The benefits of statin therapy - What questions remain?

Antonio M. Gotto, John C. LaRosa

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations


Early hydroxymethylglutaryl-CoA reductase inhibitor (statin) trials provided the first evidence of the benefits of statin therapy in secondary prevention of coronary heart disease (CHD). Outcomes data from more recent trials involving atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin, have since expanded the patient population shown to benefit from statin therapy. Current studies are evaluating the benefits of lowering lipid levels with statins to below current goals, as well as examining benefits in special patient populations and evaluating the value of surrogate markers of CHD. Early trials provided a solid foundation of knowledge on the efficacy and safety of statins. Recent and ongoing trials generate new data to resolve remaining questions in the fields of CHD prevention and lipidology.

Original languageEnglish (US)
Pages (from-to)499-503
Number of pages5
JournalClinical Cardiology
Issue number11
StatePublished - Nov 2005


  • Atherosclerosis
  • Cerebrovascular disease
  • Clinical trials
  • Coronary heart disease
  • Low-density lipoprotein cholesterol
  • Peripheral vascular disease
  • Statins

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'The benefits of statin therapy - What questions remain?'. Together they form a unique fingerprint.

Cite this